pralsetinib

RET inhibitor

Also Known As:

BLU-667; Cyclohexanecarboxamide, N-((1S)-1-(6-(4-fluoro-1H-pyrazol-1-yl)-3-pyridinyl)ethyl)-1-methoxy-4-(4-methyl-6-((5-methyl-1H-pyrazol-3-yl)amino)-2-pyrimidinyl)-, trans-; gavreto; trans-N-((1S)-1-(6-(4-Fluoro-1H-pyrazol-1-yl)-3-pyridinyl)ethyl)-1-methoxy-4-(4-methyl-6-((5-methyl-1H-pyrazol-3-yl)amino)-2-pyrimidinyl)cyclohexanecarboxamide

Networked: 102 relevant articles (10 outcomes, 13 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds

Experts

1.	Subbiah, Vivek: 8 articles (01/2022 - 01/2018)
2.	Gainor, Justin F: 5 articles (01/2022 - 01/2018)
3.	Drilon, Alexander: 4 articles (01/2022 - 10/2020)
4.	Hu, Mimi I: 4 articles (01/2022 - 01/2018)
5.	Garralda, Elena: 3 articles (01/2021 - 01/2018)
6.	Lin, Jessica J: 2 articles (01/2022 - 01/2021)
7.	Liu, Stephen V: 2 articles (01/2022 - 01/2021)
8.	Wirth, Lori J: 2 articles (01/2022 - 01/2021)
9.	Beaver, Julia A: 2 articles (10/2021 - 07/2021)
10.	Bradford, Diana: 2 articles (10/2021 - 07/2021)

Related Diseases

1.	Neoplasms (Cancer) 01/01/2022 - "These data validate RET as a tissue-agnostic target with sensitivity to RET inhibition, indicating pralsetinib's potential as a well-tolerated treatment option with rapid, robust and durable anti-tumor activity in patients with diverse RET fusion-positive solid tumors." 01/01/2022 - "Pan-cancer efficacy of pralsetinib in patients with RET fusion-positive solid tumors from the phase 1/2 ARROW trial." 10/01/2023 - "Two drugs for RET-altered cancers (Retevmo and Gavreto)." 10/01/2022 - "ARROW: pralsetinib hits target across cancers." 01/01/2022 - "ARROW ( NCT03037385 , ongoing) was designed to evaluate pralsetinib efficacy and safety in patients with advanced RET-altered solid tumors. "
2.	Thyroid Neoplasms (Thyroid Cancer) 01/01/2019 - "The experimental RET inhibitor BLU-667 appears safe and effective in patients with RET-altered thyroid cancers, according to findings presented at the 2019 American Society of Clinical Oncology Annual Meeting. " 11/27/2023 - "In this updated analysis of the ARROW study, pralsetinib continued to show deep and durable clinical activity and a manageable safety profile in patients with advanced/metastatic RET-altered thyroid cancer." 11/27/2023 - "Primary data from the open-label, phase 1/2 ARROW study demonstrated clinical activity and manageable safety with pralsetinib, a selective RET inhibitor, in patients with advanced/metastatic RET-altered thyroid cancer. " 11/27/2023 - "Pralsetinib in Patients with Advanced/metastatic RET-altered Thyroid Cancer: Updated Efficacy and Safety Data from the ARROW Study." 01/01/2021 - "Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study."
3.	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 11/02/2023 - "Pralsetinib in patients with RET fusion-positive non-small cell lung cancer: A plain language summary of the ARROW study." 10/15/2023 - "As part of the global, phase 1/2 ARROW trial (NCT03037385), the efficacy and safety of pralsetinib in Chinese patients with advanced RET fusion-positive non-small cell lung cancer (NSCLC) were evaluated. " 09/28/2023 - "The ARROW study demonstrated favorable clinical efficacy and safety of pralsetinib (PRL) in treating rearranged during transfection (RET) fusion positive non-small cell lung cancer (NSCLC) in clinical trials. " 12/01/2022 - "The selective RET-inhibitor pralsetinib has shown therapeutic activity in early clinical trials in patients with non-small cell lung cancer (NSCLC) harboring rearranged during transfection (RET) gene fusions. " 01/01/2021 - "Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study."
4.	Adenocarcinoma of Lung 01/01/2021 - "[Efficacy of pralsetinib in a patient with advanced lung adenocarcinoma positive for RET rearrangement: the importance of Comprehensive Genomic Profiling.]" 12/01/2022 - "Small Cell Transformation in a Patient With RET Fusion-Positive Lung Adenocarcinoma on Pralsetinib." 06/01/2022 - "Pralsetinib treatment for multiple RET fusions in lung adenocarcinoma: a case report." 01/01/2022 - "Corrigendum: Case report: A novel intergenic MIR4299/MIR8070-RET fusion with RET amplification and clinical response to pralsetinib in a lung adenocarcinoma patient." 01/01/2022 - "These findings broaden the range of RET fusion types and provide the basis for the hypothesis that RET intergenic fusion and amplification respond to pralsetinib treatment in lung adenocarcinoma."
5.	Disease Progression 04/01/2022 - "In the phase I/II ARROW clinical trial, pralsetinib significantly improved the overall remission rate and disease progression-free survival (PFS) of RET fusion-positive NSCLC patients. " 11/01/2022 - "Patients initiated pralsetinib at the recommended phase II dose of 400 mg once daily until disease progression, intolerance, consent withdrawal, or investigator's decision. " 01/01/2021 - "Phase 2 primary endpoints assessed for patients who received 400 mg once-daily oral pralsetinib until disease progression, intolerance, withdrawal of consent, or investigator decision, were overall response rate (Response Evaluation Criteria in Solid Tumours version 1.1; masked independent central review) and safety. " 01/01/2021 - "In phase 2, patients received 400 mg once-daily oral pralsetinib, and could continue treatment until disease progression, intolerance, withdrawal of consent, or investigator decision. "

Related Drugs and Biologics

1.	selpercatinib
2.	alectinib
3.	osimertinib
4.	Platinum
5.	anlotinib
6.	cabozantinib
7.	vandetanib (ZD6474)
8.	lenvatinib
9.	Tyrosine Kinase Inhibitors
10.	Protein-Tyrosine Kinases (Tyrosine Kinase)

Related Therapies and Procedures

1.	Therapeutics
2.	Drug Therapy (Chemotherapy)
3.	Neoadjuvant Therapy
4.	Salvage Therapy
5.	Aftercare (After-Treatment)